Skip to main content

Advertisement

SpringerLink
Log in

Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review

  • Original Article
  • Published:
Archives of Osteoporosis Aims and scope Submit manuscript

A Correction to this article was published on 08 May 2018

This article has been updated

Abstract

Summary

Osteoporosis (OP) causes reduced bone strength and increases risk of fractures. Medical records from specialist clinics in Japan of postmenopausal women with OP and high risk of fracture were analysed. Majority of patients were treated for OP as recommended and were prescribed OP medications soon after high-risk OP diagnosis.

Purpose

The incidence of osteoporosis (OP) in Japan is predicted to increase significantly in coming decades. Resultant osteoporotic fractures are a significant contributor of economic and social burden among elderly osteoporosis patients. This retrospective chart review was conducted as a response to the current evidence gap in the treatment patterns for OP patients with high risk of fracture in Japan.

Methods

This was a multi-centre retrospective chart review that analysed data extracted from the medical records of postmenopausal OP patients at high risk for fracture who received care at 11 specialist clinics and medical centers in Japan for at least 18 to 24 months. Main outcome was OP treatment patterns.

Results

The study included 709 eligible patients of whom 623 (87.9%) were prescribed OP medication during the study period. The most common reason for not taking OP medication was patient unwillingness to take medication. The most common OP medications prescribed initially were minodronic acid (20.1%), alendronate (19.9%), raloxifene (14.1%), weekly teriparatide acetate (12.4%) and eldecalcitol (11.4%). Majority of patients (62.1%) were still taking their initial medication at the end of the 18–24 month follow-up.

Conclusions

A high percentage of patients (87.9%) in Japan received OP medications soon after their high-risk diagnosis, with bisphosphonates, selective estrogen receptor modulators and teriparatide being the predominant treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

  • 08 May 2018

    In this article it was mistakenly stated that Akimitsu Miyauchi is affiliated with both Miyauchi Medical Center, Osaka and Amgen Astellas BioPharma K.K., Tokyo. In fact he is affiliated only with Miyauchi Medical Center; he has no connection with Amgen Astellas.

References

  1. Lau EM, Cooper C (1996) The epidemiology of osteoporosis. The oriental perspective in a world context Clinical orthopaedics and related research 323:65–74

    Article  Google Scholar 

  2. Orimo H, Yaegashi Y, Hosoi T, Fukushima Y, Onoda T, Hashimoto T, Sakata K (2016) Hip fracture incidence in Japan: estimates of new patients in 2012 and 25-year trends. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 27(5):1777–1784

    Article  CAS  Google Scholar 

  3. Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, Ishibashi H, Kawaguchi H, Nakamura K, Akune T (2009) Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27(5):620–628

    Article  Google Scholar 

  4. Hagino H, Sawaguchi T, Endo N, Ito Y, Nakano T, Watanabe Y (2012) The risk of a second hip fracture in patients after their first hip fracture. CalcifTissue Int 90(1):14–21

    CAS  Google Scholar 

  5. Sato M, Vietri J, Flynn JA, Fujiwara S (2014) Treatment for osteoporosis among women in Japan: associations with patient characteristics and patient-reported outcomes in the 2008-2011 Japan National Health and wellness surveys. J Osteoporos 2014:9

    Article  Google Scholar 

  6. Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis-executive summary. Arch Osteoporos 7(1–2):3–20

    Article  Google Scholar 

  7. Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31(3):247–257

    Article  Google Scholar 

  8. Fujiwara S, Hamaya E, Goto W, Masunari N, Furukawa K, Fukunaga M, Nakamura T, Miyauchi A, Chen P (2011) Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk in Japan. Bone 49(3):520–525

    Article  Google Scholar 

  9. Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Development KJA (2008) Application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 19(4):429–435

    Article  CAS  Google Scholar 

  10. Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 20(8):1429–1437

    Article  CAS  Google Scholar 

  11. Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47(3):493–502

    Article  CAS  Google Scholar 

  12. Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97(9):3097–3106

    Article  CAS  Google Scholar 

  13. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial. Lancet (London, England) 386(9999):1147–1155

    Article  CAS  Google Scholar 

  14. Jonsson E, Eriksson D, Akesson K, Ljunggren O, Salomonsson S, Borgstrom F, Strom O (2015) Swedish osteoporosis care. Arch Osteoporos 10:222

    Article  Google Scholar 

  15. Weaver J, Sajjan S, Lewiecki EM, Harris ST (2017) Diagnosis and treatment of osteoporosis before and after fracture: a side-by-side analysis of commercially insured and Medicare advantage osteoporosis patients. Journal of Managed Care & Specialty Pharmacy 23(7):735–744

    Article  Google Scholar 

  16. Mithal A, Bansal B, Kyer CS, Ebeling P (2014) The Asia-Pacific regional audit-epidemiology, costs, and burden of osteoporosis in India 2013: a report of international osteoporosis foundation. Indian Journal of Endocrinology and Metabolism 18(4):449–454

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the 11 site investigators (Osteoporosis Specialist) for conducting this study: Dr. Junichi Takada (Kitago Orthopedic Clinic, Hokkaido), Dr. Masanari Omata (Ooimachi Orthopaedic Surgery Clinic, Tokyo), Dr. Fumitoshi Ohmura (Koenji Orthopedic Clinic, Tokyo), Dr. Hiroaki Shibata (Shibata Orthopaedic Clinic, Tokyo), Dr. Masayuki Fukuchi (Fukuchi Clinic, Kikugawa-shi, Shizuoka), Dr. Akimitsu Miyauchi (Miyauchi Medical Center, Osaka), Dr. Hideki Tanaka (Okubo Hospital, Akashi-shi, Hyogo), Dr. Yasufumi Ohnishi (Onishi Medical Clinic, Kako-gun, Hyogo), Dr. Nobukazu Okimoto (Okimoto Clinic, Kures-hi, Hiroshima), Dr. Shigeki Hidaka (Hidaka Orthopedic Clinic, Kurume-shi, Fukuoka) and Dr. Shinobu Arita (Obase Hospital, Fukuoka).

Funding

Funding for this study was provided by Amgen Inc.

Author information

Authors and Affiliations

  1. Hiroshima Atomic Bomb Casualty Council, Hiroshima, Japan

    Saeko Fujiwara

  2. Miyauchi Medical Center, JR Takatsuki station NK building 2F, 1-1-1 Akutagawa-cho, Takatsuki-shi, Osaka, 569-1123, Japan

    Akimitsu Miyauchi

  3. Amgen Astellas BioPharma K.K, Tokyo, Japan

    Akimitsu Miyauchi & Etsuro Hamaya

  4. Real World Evidence Asia Pacific, Mapi, Lyon, France

    Rebecca Jayne Nicholls

  5. HEOR Asia Pacific Optum, Sydney, Australia

    Adele Weston & Santwona Baidya

  6. Amgen Inc., Thousand Oaks, CA, USA

    Lionel Pinto & Rich Barron

  7. Kitago Orthopedic Clinic, Hokkaido, Japan

    Junichi Takada

Authors
  1. Saeko Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akimitsu Miyauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Etsuro Hamaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rebecca Jayne Nicholls
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Adele Weston
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Santwona Baidya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lionel Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rich Barron
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Junichi Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akimitsu Miyauchi.

Ethics declarations

Conflict of interest

Drs. Miyauchi and Fujiwara received consulting fees from Amgen Astellas BioPharma K.K. and Dr. Fujiwara is on the Speakers Bureau of Asahi-Kasei Pharma, Alere Medical and Pfizer. Ms. Nicholls is a full-time employee of MAPI Real World Evidence. Mr. Hamaya is a full-time employee of Amgen Astellas Biopharma K.K. and owns stock in Amgen, Inc. and Eli Lilly. Drs. Weston and Baidya are full-time employees of Optum. Mr. Barron and Mr. Pinto are full-time employees of and shareholders in Amgen Inc. Dr. Takada has no disclosures related to this manuscript.

Electronic supplementary material

ESM 1

(DOCX 84 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fujiwara, S., Miyauchi, A., Hamaya, E. et al. Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review. Arch Osteoporos 13, 34 (2018). https://doi.org/10.1007/s11657-018-0443-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11657-018-0443-7

Keywords

Search

Navigation